-
胃是结外淋巴瘤最常见的发病部位,占淋巴瘤所有发病部位的30%~40%,胃淋巴瘤包括原发性胃淋巴瘤(primary gastric lymphoma,PGL)和继发性胃淋巴瘤,其在胃恶性肿瘤中的发病率仅次于胃癌[1-2]。PGL的诊断基于Dawson标准[3]:病变主要发生于胃及引流区域的淋巴结,无全身浅表淋巴结肿大,无纵隔淋巴结肿大,无肝、脾浸润,外周血白细胞分类及计数正常。PGL中以弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)和黏膜相关淋巴样组织(mucosa-associated lymphoid tissue,MALT)淋巴瘤多见,二者的治疗方法及预后有较大差异。然而PGL的临床症状并不具有特异性,缺乏特异性肿瘤标志物,且病变位于黏膜下,较易造成误诊或漏诊。18F-FDG PET/CT显像已被公认为淋巴瘤分期、疗效评估、预后预测的最佳方法[4]。但关于18F-FDG PET/CT显像用于PGL组织病理学分型和预后预测的相关文献鲜有报道。我们分析了83例PGL患者的18F-FDG PET/CT表现,对比研究 MALT淋巴瘤与 DLBCL 的18F-FDG PET/CT显像差异,探讨18F-FDG PET/CT显像在诊断PGL常见组织病理学类型和预后评估中的价值。
-
83例患者中,DLBCL患者46例,MALT淋巴瘤患者37例;>60岁患者52例;Ⅰ期患者32例,Ⅱ期24例,ⅡE期4例,Ⅳ期23例;有B症状的患者31例;15例患者缺少LDH检查结果,68例患者行LDH检查,LDH水平升高者14例;68例行LDH检查患者的IPI评分为:0~1分32例、2~5分36例。11例门诊患者缺少Ki-67的免疫组织化学检查结果。
-
胃部病灶累及贲门和胃底的患者29例、胃体56例、胃窦46例,多部位受累37例。病灶区胃壁均有不同程度增厚,其中弥漫性增厚(30例)和节段性增厚(40例)较多。胃壁僵硬者49例、胃腔肿块者11例、胃周浸润者35例,但全部患者未见明确胃腔梗阻与胃潴留。其他部位累及情况:33例仅累及胃壁,腹盆腔淋巴结浸润38例、膈上淋巴结浸润13例、小肠浸润6例、乙状结肠浸润3例、升结肠浸润2例、食管浸润2例、肺部浸润4例、肾上腺浸润2例、骨骼浸润2例、鼻咽或扁桃体浸润2例、腹膜浸润3例、双侧甲状腺浸润1例、胰腺浸润1例、上颌窦浸润1例。胃壁僵硬和胃周浸润的典型病例的CT图、PET图、18F-FDG PET/CT融合图见图1A。
-
由表1可知,DLBCL较MALT淋巴瘤更易累及胃窦、发生多部位受累,且差异均有统计学意义(χ2=11.12,3.99,P=0.001、0.046);DLBCL患者的胃壁增厚类型以弥漫性增厚和节段性增厚为多,MALT淋巴瘤患者的胃壁增厚类型以节段性增厚为多,2组患者胃壁增厚类型的差异有统计学意义(Z=4.13,P=0.042)。胃壁增厚的典型病例的CT图、PET图、18F-FDG PET/CT融合图见图1B。DLBCL患者的胃壁厚度、TLG、SUVmax均高于MALT淋巴瘤患者,且差异均有统计学意义(Z=−3.72、−4.24,t=−9.30,均P<0.001);DLBCL患者的MTV高于MALT淋巴瘤患者,但差异无统计学意义;DLBCL患者较MALT淋巴瘤患者更易发生胃周浸润及胃腔肿块,且差异均有统计学意义(χ2=11.56、6.46,P=0.001、0.011)。
项目 DLBCL患者(n=46) MALT淋巴瘤患者(n=37) 检验值 P值 病变部位(例,%) 贲门及胃底 18(39.1) 11(29.7) χ2=0.80 0.372 胃体 28(60.9) 28(75.7) χ2=2.05 0.152 胃窦 33(71.7) 13(35.1) χ2=11.12 0.001 多部位受累 25(54.3) 12(32.4) χ2=3.99 0.046 胃壁增厚类型(例,%) χ2=4.13 0.042 弥漫性 20(43.5) 10(27.0) − − 节段性 22(47.8) 18(48.6) − − 局限性 4(8.7) 9(24.3) − − 代谢参数 TLG[g,M(Q1,Q3)] 603.2(138.8,1971.0) 69.9(22.3,208.3) Z=−4.24 <0.001 MTV[cm3,M(Q1,Q3)] 40.9(11.6,93.3) 22.7(9.8,44.9) Z=−1.56 0.118 SUVmax( )$\bar x\pm s $ 23.4±11.5 6.6±3.9 t=−9.30 <0.001 胃壁厚度[mm,M(Q1,Q3)] 20.5(13.0,32.3) 12.0(10.0,16.5) Z=−3.72 <0.001 胃壁形态(例,%) 胃周浸润 27(58.7) 8(21.6) χ2=11.56 0.001 胃壁僵硬 30(65.2) 19(51.4) χ2=1.63 0.202 胃腔肿块 10(21.7) 1(2.7) χ2=6.46 0.011 胃外浸润(例,%) 淋巴结浸润 30(65.2) 18(48.6) χ2=2.31 0.129 远处器官浸润 11(23.9) 9(24.3) χ2=0.00 0.965 注:−表示无此项数据。DLBCL为弥漫性大B细胞淋巴瘤;MALT为黏膜相关淋巴样组织;FDG为氟脱氧葡萄糖;PET为正电子发射断层显像术;CT为计算机体层摄影术;TLG为病灶糖酵解总量;MTV为肿瘤代谢体积;SUVmax为最大标准化摄取值 表 1 DLBCL和MALT淋巴瘤患者的18F-FDG PET/CT显像特征和代谢参数比较
Table 1. Comparison of 18F-FDG PET/CT imaging features and metabolic parameters of patients with diffuse large B-cell lymphoma and mucosa-associated lymphoid tissue lymphoma
ROC曲线分析结果显示,18F-FDG PET/CT代谢参数中SUVmax的AUC最大,当临界值为11.95时,AUC最大为0.915,灵敏度为80.4%,特异度为91.9%,约登指数为0.723;TLG和胃壁厚度对DLBCL和MALT淋巴瘤有一定的鉴别诊断价值(AUC=0.772、0.738,均P<0.001,表2、图2)。
项目 AUC 临界值 灵敏度(%) 特异度(%) 约登指数 P值 TLG(g) 0.772 123.73 80.4 73.0 0.534 <0.001 MTV(cm3) 0.600 47.28 47.8 81.1 0.289 0.118 SUVmax 0.915 11.95 80.4 91.9 0.723 <0.001 胃壁厚度(mm) 0.738 14.50 67.4 70.3 0.377 <0.001 注:FDG为氟脱氧葡萄糖;PET为正电子发射断层显像术;CT为计算机体层摄影术;MALT为黏膜相关淋巴样组织;DLBCL为弥漫性大B细胞淋巴瘤;TLG为病灶糖酵解总量;MTV为肿瘤代谢体积;SUVmax为最大标准化摄取值 表 2 18F-FDG PET/CT代谢参数和胃壁厚度对83例MALT淋巴瘤与DLBCL患者的鉴别诊断效能
Table 2. Differential diagnostic efficacy of 18F-FDG PET/CT metabolic parameters and gastric wall thickness in 83 patients with mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma
-
83例患者的中位随访时间为32(11,50)月。14例患者肿瘤进展或复发,其中包括9例DLBCL患者、5例MALT淋巴瘤患者;9例患者死亡,其中包括8例DLBCL患者、1例MALT淋巴瘤患者。DLBCL患者的3年PFS率为80.4%(37/46),MALT淋巴瘤患者的3年PFS率为91.9%(34/37),差异无统计学意义(χ2=1.125,P=0.289)。但DLBCL患者的3年内病死率(8/46,17.4%)显著高于MALT淋巴瘤患者(1/37,2.7%),且差异有统计学意义(χ2=4.576,P=0.032)(图3、4)。
图 3 46例DLBCL患者的胃壁厚度及18F-FDG PET/CT代谢参数SUVmax、MTV、TLG对其无进展生存率的Kaplan-Meier生存分析曲线
Figure 3. Kaplan-Meier survival analysis curves of gastric wall thickness and metabolic parameters maximum standardized uptake value, metabolic tumor volume and total lesion glycolysis of 18F-FDG for progression-free survival rate in 46 patients with diffuse large B-cell lymphoma
图 4 37例MALT淋巴瘤患者的临床参数对其无进展生存率的Kaplan-Meier生存分析曲线
Figure 4. Kaplan-Meier survival analysis curves of progression-free survival rate based on clinical parameters of 37 patients with mucosa-associated lymphoid tissue lymphoma
ROC曲线分析结果显示,SUVmax、TLG、MTV、胃壁厚度、Ki-67判断DLBCL患者PFS期的最佳临界值分别为:27.68、1135.99 g、72.9 cm3、29.5 mm、87.5%。将各参数按临界值分组,Kaplan-Meier分析结果显示,胃壁厚度(≤29.5 mm)、SUVmax(≤27.68)、MTV(≤72.9 cm3)、TLG(≤1135.99 g)的3年PFS率大于胃壁厚度(>29.5 mm)、SUVmax(>27.68)、MTV(>72.9 cm3)、TLG(>1135.99 g)(92.6%对43.2%、93.0%对52.2%、91.7%对55.4%、83.5%对53.0%),差异均有统计学意义(χ2=6.98~12.71,均P<0.01,图3)。Lugano分期( Ⅰ~Ⅱ期、ⅡE ~Ⅳ期)、IPI(0~1分、2~5分)、B症状(有、无)、性别(男、女)、年龄(≤60、>60岁)、Ki-67(≤87.5%、>87.5%)、胃壁增厚类型(局限性、节段性、弥漫性)组间PFS率的差异均无统计学意义(χ2=0.13~3.79,均P>0.05)。
ROC曲线分析结果显示,SUVmax、TLG、MTV、胃壁厚度、Ki-67判断MALT淋巴瘤患者PFS期的最佳临界值分别为:3.55、34.82 g、12.615 cm3、22 mm、7.5%。将各参数按临界值分组,Kaplan-Meier生存分析结果显示,Lugano分期(ⅡE~Ⅳ期)、年龄(>60岁)、IPI(2~5分)、Ki-67(≤7.5%)、胃壁弥漫性增厚的3年PFS率均小于Lugano分期(Ⅰ~Ⅱ期)、年龄(≤60岁)、IPI(0~1分)、Ki-67(>7.5%)和胃壁节段性增厚及局限性增厚(65.6%对100.0%、74.3%对100.0%、64.3%对100.0%、50.0%对88.3%、95.2%对72.9%),且差异均有统计学意义 (χ2=4.31~15.11,均P<0.05,图4)。而B症状(有、无)、性别(男、女)、胃壁厚度、SUVmax、TLG、MTV组间PFS率的差异无统计学意义(χ2=0.28~3.35,均P>0.05)。
单因素Cox回归分析结果显示,胃壁厚度、SUVmax、TLG、MTV均为DLBCL患者PFS期的危险因素(HR=5.749~8.768,均P<0.05,表3);胃壁增厚类型为MALT患者PFS期的危险因素(HR=8.683,P=0.022,表4)。因MALT淋巴瘤患者PFS期的危险因素仅有胃壁增厚类型,因此只对DLBCL患者行多因素回归分析,结果显示,SUVmax为DLBCL患者PFS期的独立危险因素(HR=9.317,P=0.047,表3)。
因素 例数 单因素分析 多因素分析 HR 95%CI Wald值 P值 HR 95%CI Wald值 P值 性别(女/男) 25/21 0.358 0.089~1.442 2.087 0.149 2.750 0.508~14.886 1.379 0.240 年龄(≤60/>60岁) 32/14 0.398 0.107~1.484 1.883 0.170 3.510 0.808~15.239 2.808 0.094 增厚类型(局限性、节段性/弥漫性增厚) 26/20 3.459 0.840~13.915 3.054 0.081 0.538 0.049~5.859 0.259 0.611 SUVmax(≤27.68/>27.68) 29/17 6.607 1.321~33.049 5.284 0.022 9.317 1.030~84.318 3.944 0.047 胃壁厚度(≤29.5/>29.5 mm) 33/13 8.768 2.126~36.162 9.020 0.003 8.256 0.198~344.849 1.229 0.268 TLG(g,≤1 135.99/>1 135.99) 31/15 6.220 1.542~25.089 6.599 0.010 0.060 0.000~14.519 1.009 0.315 MTV(cm3,≤72.9/>72.9) 30/16 5.749 1.420~23.270 6.011 0.014 12.254 0.153~982.270 1.255 0.263 注:DLBCL为弥漫性大B细胞淋巴瘤;Cox为生存分析;SUVmax为最大标准化摄取值;TLG为病灶糖酵解总量;MTV为肿瘤代谢体积;HR 为风险比;CI为置信区间 表 3 46例DLBCL患者无进展生存期影响因素的Cox回归分析
Table 3. Cox regression analysis of the influencing factors of progression-free survival time in 46 diffuse large B-cell lymphoma patients
因素 例数 HR 95%CI Wald值 P值 性别(女/男) 19/18 0.619 0.103~3.726 0.274 0.601 年龄(≤60/>60岁) 20/17 0.136 0.015~1.228 3.156 0.076 Lugano 分期(Ⅰ~Ⅱ/ⅡE ~Ⅳ) 27/10 0.003 0~53.040 1.362 0.243 IPI评分(0~1/2~5分) 17/11 0.007 0~18.208 1.534 0.216 胃壁增厚类型(局限性、节段性/弥漫性增厚) 27/10 8.683 1.363~55.325 5.232 0.022 注:MALT为黏膜相关淋巴样组织;Cox为生存分析;IPI为国际预后指数;HR为风险比;CI为置信区间 表 4 37例MALT淋巴瘤患者无进展生存期影响因素的单因素Cox回归分析
Table 4. Univariate Cox regression analysis of the influencing factors of progression-free survival time in 37 mucosa-associated lymphoid tissue lymphoma patients
18F-FDG PET/CT在常见原发性胃淋巴瘤组织病理学分型鉴别诊断和预后评估中的价值
The value of 18F-FDG PET/CT in differential diagnosis and prognosis evaluation of histopathological classification of common primary gastric lymphoma
-
摘要:
目的 探讨18F-氟脱氧葡萄糖(FDG) PET/CT在常见原发性胃淋巴瘤(PGL)[弥漫性大B细胞淋巴瘤(DLBCL)和黏膜相关淋巴样组织(MALT)淋巴瘤]组织病理学分型鉴别诊断和预后评估中的价值。 方法 回顾性分析2015年3月至2022年3月于中南大学湘雅二医院行18F-FDG PET/CT检查的83例PGL患者的临床资料和影像资料,其中男性39例、女性44例,年龄范围为13~78岁,中位年龄为56(48,66)岁。根据组织病理学类型将患者分为DLBCL(46例)和MALT淋巴瘤(37 例),比较2种类型PGL患者的临床特征[性别、年龄、Lugano分期、B症状、乳酸脱氢酶(LDH)水平、国际预后指数(IPI)、细胞增殖核抗原Ki-67(简称Ki-67)水平]、影像特征(胃壁厚度、胃壁增厚类型、病变部位、胃壁形态、胃外浸润)、代谢参数[最大标准化摄取值(SUVmax)、病灶糖酵解总量(TLG)、肿瘤代谢体积(MTV)]间的差异。计数资料用频数和百分比表示,组间比较采用卡方检验或Fisher确切概率法;符合正态分布的计量资料以 $\bar x\pm s $ 表示,组间比较采用两独立样本t检验;不符合正态分布的计量资料以M(Q1,Q3)表示,组间比较采用Mann-Whitney U检验。采用受试者工作特征(ROC)曲线分析代谢参数和胃壁厚度对鉴别DLBCL与MALT淋巴瘤的价值,对各代谢参数判断疾病进展的最佳临界值进行分类;采用Kaplan-Meier 法进行生存分析,组间差异评估采用Log-rank法,对可能影响无进展生存(PFS)期的因素进行单因素和多因素Cox回归分析。结果 DLBCL较MALT淋巴瘤更易发生胃周浸润、胃腔肿块、胃窦受累、多部位受累和胃壁弥漫性增厚,且差异均有统计学意义(58.7%对21.6%、21.7%对2.7%、71.7%对35.1%、54.3%对32.4%、43.5%对27.0%,χ2=3.99~11.56,均P<0.05);DLBCL患者的胃壁厚度、TLG、SUVmax显著高于MALT淋巴瘤患者[20.5(13.0,32.3) mm 对 12.0(10.0,16.5) mm、603.2(138.8,1971.0) g 对 69.9(22.3,208.3) g、23.4±11.5 对 6.6±3.9],差异均有统计学意义(Z=−3.72、−4.24,t=−9.30,均P<0.05)。ROC曲线分析结果显示,SUVmax、TLG、胃壁厚度对鉴别MALT淋巴瘤与DLBCL诊断效能的差异均有统计学意义(AUC=0.915、0.772、0.738,均P<0.05),当SUVmax=11.95为临界值时,灵敏度为80.4%,特异度为91.9%。Kaplan-Meier 生存分析结果显示,DLBCL患者的胃壁厚度、SUVmax、TLG、MTV与PFS率相关,差异均有统计学意义(χ2=6.98~12.71,均P<0.01);MALT淋巴瘤患者的年龄、Lugano分期、IPI、Ki-67、胃壁弥漫性增厚与PFS率相关,差异均有统计学意义(χ2=4.31~15.11,均P<0.05)。单因素Cox回归分析结果显示,胃壁厚度、SUVmax、TLG、MTV为DLBCL 患者PFS期的危险因素(HR=5.749~8.768,均P<0.05);胃壁增厚类型为MALT淋巴瘤患者PFS期的危险因素(HR=8.683,P=0.022)。多因素回归分析结果显示,SUVmax为DLBCL患者PFS期的独立危险因素(HR=9.317,P=0.047)。 结论 DLBCL和MALT淋巴瘤的18F-FDG PET/CT显像有一定特征性,18F-FDG PET/CT代谢参数既可以鉴别DLBCL与MALT淋巴瘤,同时也可以预测DLBCL患者的预后。 -
关键词:
- 氟脱氧葡萄糖F18 /
- 正电子发射断层显像术 /
- 体层摄影术,X线计算机 /
- 胃 /
- 淋巴瘤,大B细胞,弥漫性 /
- 黏膜相关淋巴样组织淋巴瘤
Abstract:Objective To investigate the value of 18F-fluorodeoxyglucose (FDG) PET/CT in the histopathological classification and prognosis of common primary gastric lymphoma (PGL) (diffuse large B-cell lymphoma (DLBCL) and mucosa-associated lymphoid tissue (MALT) lymphoma). Methods The clinical and imaging data of 83 patients with PGL who underwent 18F-FDG PET/CT at the Second Xiangya Hospital of Central South University from March 2015 to March 2022 were retrospectively analyzed. The patients included 39 males and 44 females aged 13–78 years old with a median age of 56 (48, 66) years. DLBCL (46 cases) and MALT lymphoma (37 cases) were classified in accordance with histopathological type to compare the clinical characteristics (sex, age, Lugano stage, B symptoms, lactate dehydrogenase level, international prognostic index (IPI), and cell proliferating nuclear antigen Ki-67 (Ki-67) level), imaging features (gastric wall thickness, gastric wall thickening type, lesion site, gastric wall morphology, and extragastric infiltration), and metabolic parameters (maximum standardized uptake value (SUVmax), total lesion glycolysis (TLG)) and metabolic tumor volume (MTV)) of the two types of patients with PGL. Counting data were expressed as frequency and percentage, and comparison between groups was performed by using chi-square test or Fisher's exact probability method. Measurement data conforming to normal distribution were expressed as $\bar x\pm s $ , and comparison between groups was performed by using two independent samples t-test. Measurement data not conforming to normal distribution were expressed as M (Q1, Q3), and the Mann-Whitney U test was employed for comparison between groups. Receiver operating characteristic (ROC) curves were applied to analyze the value of metabolic parameters and gastric wall thickness in differentiating DLBCL from MALT lymphoma. The optimal cut-off values for predicting disease progression were calculated using SUVmax, TLG, MTV, gastric wall thickness, and Ki-67. According to these values, classifications were made. The Kaplan-Meier method was utilized for survival analysis. The Log-rank method was used to assess differences between groups, and univariate and multivariate Cox regression analysis was performed for factors that may affect progression-free survival (PFS) time.Results Patients with DLBCL were more likely to have perigastric invasion, luminal mass, antral involvement, multisite involvement, and the diffuse thickening of the gastric wall than those with MALT lymphoma (58.7% vs. 21.6%, 21.7% vs. 2.7%, 71.7% vs. 35.1%, 54.3% vs. 32.4%, 43.5% vs. 27.0%, χ2=3.99–11.56, all P<0.05). The gastric wall thickness, TLG, and SUVmax of patients with DLBCL were significantly higher than those of patients with MALT lymphoma, and their differences were statistically significant (20.5 (13.0, 32.3) vs. 12.0 (10.0, 16.5) mm, 603.2 (138.8, 1 971.0) g vs. 69.9 (22.3, 208.3) g, (23.4±11.5) vs. (6.6±3.9), Z=−3.72, −4.24, t=−9.30, all P<0.05). ROC curve analysis showed that SUVmax, TLG, and gastric wall thickness had significant differences in their diagnostic power for differentiating MALT lymphoma from DLBCL (AUC=0.915, 0.772, 0.738; all P<0.05). When the critical value was SUVmax=11.95, the sensitivity was 80.4% and the specificity was 91.9%. Kaplan-Meier survival analysis revealed that gastric wall thickness, SUVmax, TLG, and MTV were significantly correlated with PFS rate (χ2=6.98–12.71, all P<0.01). Age, Lugano stage, IPI, Ki-67, and diffuse thickening of the gastric wall were significantly correlated with PFS rate (χ2=4.31–15.11, all P<0.05). Univariate Cox regression analysis demonstrated that gastric wall thickness, SUVmax, TLG, and MTV were the risk factors of PFS time in patients with DLBCL, and the differences of these factors were statistically significant (HR=5.749–8.768, all P<0.05). The type of gastric wall thickening was a risk factor of PFS time in patients with MALT lymphoma, and its difference was statistically significant (HR=8.683, P=0.022). Multivariate Cox regression analysis revealed that SUVmax was an independent risk factor of PFS time in patients with DLBCL, and its difference was statistically significant (HR=9.317, P=0.047). Conclusions The 18F-FDG PET/CT imaging of DLBCL and MALT lymphoma has certain characteristics. 18F-FDG PET/CT metabolic parameters can not only distinguish DLBCL from MALT lymphoma, it can also predict the prognosis of patients with DLBCL. -
图 3 46例DLBCL患者的胃壁厚度及18F-FDG PET/CT代谢参数SUVmax、MTV、TLG对其无进展生存率的Kaplan-Meier生存分析曲线
Figure 3. Kaplan-Meier survival analysis curves of gastric wall thickness and metabolic parameters maximum standardized uptake value, metabolic tumor volume and total lesion glycolysis of 18F-FDG for progression-free survival rate in 46 patients with diffuse large B-cell lymphoma
表 1 DLBCL和MALT淋巴瘤患者的18F-FDG PET/CT显像特征和代谢参数比较
Table 1. Comparison of 18F-FDG PET/CT imaging features and metabolic parameters of patients with diffuse large B-cell lymphoma and mucosa-associated lymphoid tissue lymphoma
项目 DLBCL患者(n=46) MALT淋巴瘤患者(n=37) 检验值 P值 病变部位(例,%) 贲门及胃底 18(39.1) 11(29.7) χ2=0.80 0.372 胃体 28(60.9) 28(75.7) χ2=2.05 0.152 胃窦 33(71.7) 13(35.1) χ2=11.12 0.001 多部位受累 25(54.3) 12(32.4) χ2=3.99 0.046 胃壁增厚类型(例,%) χ2=4.13 0.042 弥漫性 20(43.5) 10(27.0) − − 节段性 22(47.8) 18(48.6) − − 局限性 4(8.7) 9(24.3) − − 代谢参数 TLG[g,M(Q1,Q3)] 603.2(138.8,1971.0) 69.9(22.3,208.3) Z=−4.24 <0.001 MTV[cm3,M(Q1,Q3)] 40.9(11.6,93.3) 22.7(9.8,44.9) Z=−1.56 0.118 SUVmax( )$\bar x\pm s $ 23.4±11.5 6.6±3.9 t=−9.30 <0.001 胃壁厚度[mm,M(Q1,Q3)] 20.5(13.0,32.3) 12.0(10.0,16.5) Z=−3.72 <0.001 胃壁形态(例,%) 胃周浸润 27(58.7) 8(21.6) χ2=11.56 0.001 胃壁僵硬 30(65.2) 19(51.4) χ2=1.63 0.202 胃腔肿块 10(21.7) 1(2.7) χ2=6.46 0.011 胃外浸润(例,%) 淋巴结浸润 30(65.2) 18(48.6) χ2=2.31 0.129 远处器官浸润 11(23.9) 9(24.3) χ2=0.00 0.965 注:−表示无此项数据。DLBCL为弥漫性大B细胞淋巴瘤;MALT为黏膜相关淋巴样组织;FDG为氟脱氧葡萄糖;PET为正电子发射断层显像术;CT为计算机体层摄影术;TLG为病灶糖酵解总量;MTV为肿瘤代谢体积;SUVmax为最大标准化摄取值 表 2 18F-FDG PET/CT代谢参数和胃壁厚度对83例MALT淋巴瘤与DLBCL患者的鉴别诊断效能
Table 2. Differential diagnostic efficacy of 18F-FDG PET/CT metabolic parameters and gastric wall thickness in 83 patients with mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma
项目 AUC 临界值 灵敏度(%) 特异度(%) 约登指数 P值 TLG(g) 0.772 123.73 80.4 73.0 0.534 <0.001 MTV(cm3) 0.600 47.28 47.8 81.1 0.289 0.118 SUVmax 0.915 11.95 80.4 91.9 0.723 <0.001 胃壁厚度(mm) 0.738 14.50 67.4 70.3 0.377 <0.001 注:FDG为氟脱氧葡萄糖;PET为正电子发射断层显像术;CT为计算机体层摄影术;MALT为黏膜相关淋巴样组织;DLBCL为弥漫性大B细胞淋巴瘤;TLG为病灶糖酵解总量;MTV为肿瘤代谢体积;SUVmax为最大标准化摄取值 表 3 46例DLBCL患者无进展生存期影响因素的Cox回归分析
Table 3. Cox regression analysis of the influencing factors of progression-free survival time in 46 diffuse large B-cell lymphoma patients
因素 例数 单因素分析 多因素分析 HR 95%CI Wald值 P值 HR 95%CI Wald值 P值 性别(女/男) 25/21 0.358 0.089~1.442 2.087 0.149 2.750 0.508~14.886 1.379 0.240 年龄(≤60/>60岁) 32/14 0.398 0.107~1.484 1.883 0.170 3.510 0.808~15.239 2.808 0.094 增厚类型(局限性、节段性/弥漫性增厚) 26/20 3.459 0.840~13.915 3.054 0.081 0.538 0.049~5.859 0.259 0.611 SUVmax(≤27.68/>27.68) 29/17 6.607 1.321~33.049 5.284 0.022 9.317 1.030~84.318 3.944 0.047 胃壁厚度(≤29.5/>29.5 mm) 33/13 8.768 2.126~36.162 9.020 0.003 8.256 0.198~344.849 1.229 0.268 TLG(g,≤1 135.99/>1 135.99) 31/15 6.220 1.542~25.089 6.599 0.010 0.060 0.000~14.519 1.009 0.315 MTV(cm3,≤72.9/>72.9) 30/16 5.749 1.420~23.270 6.011 0.014 12.254 0.153~982.270 1.255 0.263 注:DLBCL为弥漫性大B细胞淋巴瘤;Cox为生存分析;SUVmax为最大标准化摄取值;TLG为病灶糖酵解总量;MTV为肿瘤代谢体积;HR 为风险比;CI为置信区间 表 4 37例MALT淋巴瘤患者无进展生存期影响因素的单因素Cox回归分析
Table 4. Univariate Cox regression analysis of the influencing factors of progression-free survival time in 37 mucosa-associated lymphoid tissue lymphoma patients
因素 例数 HR 95%CI Wald值 P值 性别(女/男) 19/18 0.619 0.103~3.726 0.274 0.601 年龄(≤60/>60岁) 20/17 0.136 0.015~1.228 3.156 0.076 Lugano 分期(Ⅰ~Ⅱ/ⅡE ~Ⅳ) 27/10 0.003 0~53.040 1.362 0.243 IPI评分(0~1/2~5分) 17/11 0.007 0~18.208 1.534 0.216 胃壁增厚类型(局限性、节段性/弥漫性增厚) 27/10 8.683 1.363~55.325 5.232 0.022 注:MALT为黏膜相关淋巴样组织;Cox为生存分析;IPI为国际预后指数;HR为风险比;CI为置信区间 -
[1] Juárez-Salcedo LM, Sokol L, Chavez JC, et al. Primary gastric lymphoma, epidemiology, clinical diagnosis, and treatment[J]. Cancer Control, 2018, 25(1): 1073274818778256. DOI: 10.1177/1073274818778256. [2] Olszewska-Szopa M, Wróbel T. Gastrointestinal non-Hodgkin lymphomas[J]. Adv Clin Exp Med, 2019, 28(8): 1119−1124. DOI: 10.17219/acem/94068. [3] Dawson IM, Cornes JS, Morson BC. Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis[J]. Br J Surg, 1961, 49: 80−89. DOI: 10.1002/bjs.18004921319. [4] 中华医学会核医学分会. 淋巴瘤18F-FDG PET/CT及PET/MR显像临床应用指南(2021 版)[J]. 中华核医学与分子影像杂志, 2021, 41(3): 161−169. DOI: 10.3760/cma.j.cn321828-20210129-00018.
Chinese Society of Nuclear Medicine. Clinical practice guideline of 18F-FDG PET/CT and PET/MR in lymphoma (2021 edition)[J]. Chin J Nucl Med Mol Imaging, 2021, 41(3): 161−169. DOI: 10.3760/cma.j.cn321828-20210129-00018.[5] Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification[J]. J Clin Oncol, 2014, 32(27): 3059−3068. DOI: 10.1200/jco.2013.54.8800. [6] Ishikawa E, Nakamura M, Satou A, et al. Mucosa-associated lymphoid tissue (MALT) lymphoma in the gastrointestinal tract in the modern era[J/OL]. Cancers, 2022, 14(2): 446[2023-01-17]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773811. DOI: 10.3390/cancers14020446. [7] Meignan M, Sasanelli M, Casasnovas RO, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients[J]. Eur J Nucl Med Mol Imaging, 2014, 41(6): 1113−1122. DOI: 10.1007/s00259-014-2705-y. [8] Megibow AJ, Balthazar EJ, Naidich DP, et al. Computed tomography of gastrointestinal lymphoma[J]. AJR Am J Roentgenol, 1983, 141(3): 541−547. DOI: 10.2214/ajr.141.3.541. [9] 陈宇, 石木兰, 郭向东. CT在胃原发非霍奇金淋巴瘤与胃低分化腺癌鉴别诊断中的应用价值[J]. 临床放射学杂志, 2003, 22(3): 203−206. DOI: 10.3969/j.issn.1001-9324.2003.03.008.
Chen Y, Shi ML, Guo XD. Evaluation of CT in differentiating gastric primary non-Hodgkin lymphoma with poorly differentiated adenocarcinoma[J]. J Clin Radiol, 2003, 22(3): 203−206. DOI: 10.3969/j.issn.1001-9324.2003.03.008.[10] 刘高双, 王宇晴, 李培培, 等. 原发于胃肠道的黏膜相关淋巴组织淋巴瘤及弥漫性大B细胞淋巴瘤临床表现及内镜特征的比较[J]. 南京医科大学学报: 自然科学版, 2018, 38(1): 67−71. DOI: 10.7655/NYDXBNS20180115.
Liu GS, Wang YQ, Li PP, et al. A comparative study of clinical and endoscopic features of 119 cases of patients with MALT lymphoma and diffuse large B cell lymphoma in the gastrointestinal tract[J]. J Nanjing Med Univ (Nat Sci), 2018, 38(1): 67−71. DOI: 10.7655/NYDXBNS20180115.[11] Takigawa H, Yuge R, Masaki S, et al. Involvement of non-Helicobacter pylori helicobacter infections in Helicobacter pylori-negative gastric MALT lymphoma pathogenesis and efficacy of eradication therapy[J]. Gastric Cancer, 2021, 24(4): 937−945. DOI: 10.1007/s10120-021-01172-x. [12] 谷军保, 李晓琳, 鲍学斌, 等. 内镜对原发性胃肠道黏膜相关淋巴组织淋巴瘤和弥漫性大B细胞淋巴瘤的诊断价值[J]. 中华普通外科杂志, 2018, 33(6): 493−496. DOI: 10.3760/cma.j.issn.1007-631X.2018.06.015.
Gu JB, Li XL, Bao XB, et al. Endoscopic diagnosis for primary gastrointestinal mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma[J]. Chin J Gen Surg, 2018, 33(6): 493−496. DOI: 10.3760/cma.j.issn.1007-631X.2018.06.015.[13] 胡斌, 毛秋粉, 王锦锋, 等. 18F-FDG PET/CT显像对胃部恶性肿瘤的鉴别诊断价值[J]. 重庆医学, 2016, 45(16): 2229−2232. DOI: 10.3969/j.issn.1671-8348.2016.16.022.
Hu B, Mao QF, Wang JF, et al. The differential diagnostic value of 18F-FDG PET/CT imaging on gastric malignancies[J]. Chongqing Med, 2016, 45(16): 2229−2232. DOI: 10.3969/j.issn.1671-8348.2016.16.022.[14] 陈智慧, 陈任政, 司徒敏婷, 等. 64排螺旋CT在进展期胃癌与胃淋巴瘤的诊断及鉴别诊断的应用价值[J]. 实用放射学杂志, 2020, 36(5): 756−758, 803. DOI: 10.3969/j.issn.1002-1671.2020.05.017.
Chen ZH, Chen RZ, Situ MT, et al. The value of 64-slice spiral CT in the diagnosis and differential diagnosis of advanced gastric cancer and gastric lymphoma[J]. J Pract Radiol, 2020, 36(5): 756−758, 803. DOI: 10.3969/j.issn.1002-1671.2020.05.017.[15] Diamantidis MD, Papaioannou M, Hatjiharissi E. Primary gastric non-Hodgkin lymphomas: recent advances regarding disease pathogenesis and treatment[J]. World J Gastroenterol, 2021, 27(35): 5932−5945. DOI: 10.3748/wjg.v27.i35.5932. [16] Moleiro J, Ferreira S, Lage P, et al. Gastric malt lymphoma: analysis of a series of consecutive patients over 20 years[J]. United European Gastroenterol J, 2016, 4(3): 395−402. DOI: 10.1177/2050640615612934. [17] 乔文礼, 陈香, 刘长存, 等. 18F-FDG PET/CT显像在原发性胃肠道淋巴瘤中期疗效与预后评估中的价值[J]. 中华核医学与分子影像杂志, 2022, 42(4): 202−208. DOI: 10.3760/cma.j.cn321828-20220209-00036.
Qiao WL, Chen X, Liu CC, et al. Value of 18F-FDG PET/CT in the interim therapeutic and prognostic evaluation of primary gastrointestinal lymphoma[J]. Chin J Nucl Med Mol Imaging, 2022, 42(4): 202−208. DOI: 10.3760/cma.j.cn321828-20220209-00036.[18] Schöder H, Noy A, Gönen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma[J]. J Clin Oncol, 2005, 23(21): 4643−4651. DOI: 10.1200/jco.2005.12.072. [19] Jiang C, Ding CY, Xu JY, et al. Will baseline total lesion glycolysis play a role in improving the prognostic value of the NCCN-IPI in primary gastric diffuse large B-cell lymphoma patients treated with the R-CHOP regimen?[J]. Clin Nucl Med, 2021, 46(1): 1−7. DOI: 10.1097/rlu.0000000000003378. [20] Albano D, Bosio G, Camoni L, et al. Prognostic role of baseline 18F-FDG PET/CT parameters in MALT lymphoma[J]. Hematol Oncol, 2019, 37(1): 39−46. DOI: 10.1002/hon.2563. [21] Park YJ, Hyun SH, Moon SH, et al. Role in staging and prognostic value of pretherapeutic 18F-FDG PET/CT in patients with gastric MALT lymphoma without high-grade transformation[J/OL]. Sci Rep, 2021, 11(1): 9243[2023-01-17]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084924. DOI: 10.1038/s41598-021-88815-2. [22] 蒋冲, 孙一文, 滕月, 等. 胃黏膜相关淋巴组织淋巴瘤18F-FDG PET/CT影像学与消化内镜对照研究[J]. 中华核医学与分子影像杂志, 2021, 41(11): 660−663. DOI: 10.3760/cma.j.cn321828-20200623-00249.
Jiang C, Sun YW, Teng Y, et al. Comparison of 18F-FDG PET/CT and digestive endoscopy findings in gastric mucosa-associated lymphoid tissue lymphoma[J]. Chin J Nucl Med Mol Imaging, 2021, 41(11): 660−663. DOI: 10.3760/cma.j.cn321828-20200623-00249.